Woodline Partners’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Woodline Partners’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,362,354	Closed	-$3.11M	–	735
2024 Q2	$3.11M	Buy	+1,362,354	New	+$5.2M	0.03%	384
2023 Q3	–	Sell	-150,437	Closed	-$375K	–	775
2023 Q2	$375K	Sell	150,437 -150,437	-50%	-$411K	﹤0.01%	559
2023 Q1	$806K	Sell	300,874 -728,093	-71%	-$3.5M	0.01%	490
2022 Q4	$5.59M	Buy	1,028,967 +752,067	+272%	+$6.3M	0.07%	296
2022 Q3	$3.46M	Sell	276,900 -1,520,282	-85%	-$17.4M	0.05%	363
2022 Q2	$8.88M	Buy	+1,797,182	New	+$9.95M	0.14%	190

Woodline Partners's GTHX Position: Q3 2024 in Review

Woodline Partners sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 1,362,354 shares — an estimated $3.11M sold.

Woodline Partners first reported a position in GTHX in Q2 2022 and held it in 6 quarters. The position peaked at $8.88M in Q2 2022. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

Woodline Partners reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Woodline Partners sold 1,362,354 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $3.11M.
Woodline Partners first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
Woodline Partners's G1 Therapeutics, Inc. Common Stock position peaked at $8.88M in Q2 2022.
0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.